Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
UNSPSC Code:
41106514
NACRES:
NA.81
Biological source:
human
Growth mode:
N/A
Manufacturer/tradename:
Millipore
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
VCaP-EnzR Human Enzalutamide Resistant Prostate Cell Line,
biological source
human
packaging
vial of >1X10⁶ cells
manufacturer/tradename
Millipore
growth mode
N/A
technique(s)
cell culture | mammalian: suitable
shipped in
dry ice
storage temp.
≤ − 140°C
Application
Prostate cancer (PCA) is the most frequently diagnosed cancer among men in the USA, with over 150 000 new cases expected annually. Approximately 6% become metastatic, with a 5-yr survival rate of only 29%. Metastatic lesions form most frequently in bone. Since the 1940s, the standard treatment for advanced PCA has been surgical or chemical castration targeting the androgen receptor (AR) signaling axis. Most treated patients, however, develop resistance and become androgen independent, which contributes to disease progression and poor prognosis, delineating a critical need to identify novel targetable pathways mediating resistance (1). The scientific investigation of PCA tumorigenesis and experimental therapies has been limited to a few of cell- and animal-based model systems.
Source:
Xenografted into SCID mice before propagated in cell culture, the parental PCA cell line VCaP derives from a vertebral metastatic lesion of a hormone refractory prostate cancer patient. Successfully cultured for over 50 passages in vitro, VCaP is considered an immortalized cell line (2). VCaP-EnzR is an enzalutamide resistant (EnzR) derivative of VCaP, developed by prolonged in vitro culture with enzalutamide, a second-generation AR antagonist efficacious in the treatment of castration resistant prostate cancer. VcaP-EnzR is a valuable research tool for studying castration resistant prostate cancer (3).
Biosafety Level 2
VCaP-EnzR cells contain mouse xenotropic retrovirus Bxv-1 and should be handled under biosafety level 2. The parental VCaP prostate cancer cell line is known to produce the mouse xenotropic rerovirus Bxv-1, which was likely acquired by the cells during their xenotransplantation in mice.
References:
1. Kelly SP et al. (2018) Past, current and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 4(1):121–127.
2. Korenchuk S et al. (2001) VcaP, a cell-based model system of human prostate cancer. In Vivo 15(2):163-168.
3. Kregel S et al. (2016) Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget 7(18):26259-26274.
Source:
Xenografted into SCID mice before propagated in cell culture, the parental PCA cell line VCaP derives from a vertebral metastatic lesion of a hormone refractory prostate cancer patient. Successfully cultured for over 50 passages in vitro, VCaP is considered an immortalized cell line (2). VCaP-EnzR is an enzalutamide resistant (EnzR) derivative of VCaP, developed by prolonged in vitro culture with enzalutamide, a second-generation AR antagonist efficacious in the treatment of castration resistant prostate cancer. VcaP-EnzR is a valuable research tool for studying castration resistant prostate cancer (3).
Biosafety Level 2
VCaP-EnzR cells contain mouse xenotropic retrovirus Bxv-1 and should be handled under biosafety level 2. The parental VCaP prostate cancer cell line is known to produce the mouse xenotropic rerovirus Bxv-1, which was likely acquired by the cells during their xenotransplantation in mice.
References:
1. Kelly SP et al. (2018) Past, current and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 4(1):121–127.
2. Korenchuk S et al. (2001) VcaP, a cell-based model system of human prostate cancer. In Vivo 15(2):163-168.
3. Kregel S et al. (2016) Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget 7(18):26259-26274.
Features and Benefits
VCaP-EnzR Human Enzalutamide Resistant Prostate Cell Line is a valuable research model for studying castration resistant prostate cancer
Preparation Note
Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
Other Notes
Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact licensing@milliporesigma.com.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Classe de stockage
10 - Combustible liquids
Que se passe-t-il ?
WGK 2
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.